Clinical Trial Update: Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating nivolumab in multiple myeloma patients who previously received idecabtagene vicleucel (ide-cel).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Idecabtagene vicleucel (idecabtagene vicleucel)
• nivolumab (nivolumab)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING